Incyte Points To Niktimvo, Three Near-Term Approvals For Growth

 
• By Joseph Haas
  
Incyte points to pending approvals, Phase III readouts and initiations as potential growth drivers (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Anticancer